Academic Proceedings
Editor’s Note: At a recent international uro-oncology symposium, Dr. Takemura K. from the Department of Genitourinary Oncology at the Japanese Foundation for Cancer Research (JFCR), Ariake Hospital, presented findings from a multicenter retrospective study investigating the correlation between the time-of-day administration (ToDA) of first-line immune checkpoint inhibitors (ICIs) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
01 Background: The Potential Link Between Circadian Rhythms and Immunotherapy
The circadian rhythm acts as an internal biological clock with significant regulatory effects on the immune system. While previous evidence suggests that circadian rhythms may influence clinical outcomes, data regarding the impact of ICI administration timing in the era of combination immunotherapy for mRCC remains limited. This study sought to assess the association between ToDA of ICIs and OS in patients receiving contemporary first-line therapies.
02 Study Design: Cohort Stratification Based on Median Administration Time
This multicenter study included 306 patients with mRCC from three cancer centers in Japan and Canada. Patients were categorized into two cohorts based on the median time of ICI administration over the initial four treatment cycles:
• Morning Cohort: 110 patients.
• Afternoon Cohort: 196 patients.
Baseline characteristics were generally well-balanced between the two groups, with the exception of the first-line regimen; a higher proportion of patients in the morning cohort received ICI+ICI dual therapy, while more patients in the afternoon cohort received ICI+TKI (tyrosine kinase inhibitor) combinations.
03 Survival Data: Significant OS Improvement with Morning Administration
The results demonstrated a significant correlation between administration timing and patient survival. The median OS for the morning cohort reached 54 months, compared to 28 months for the afternoon cohort. This disparity underscores the potential clinical benefit of morning ICI infusions in extending the survival of mRCC patients.
04 Multivariate Analysis: Timing as an Independent Prognostic Factor
To mitigate selection bias, a multivariate analysis for OS was performed. After adjusting for potential confounders including the specific treatment regimens, morning administration remained independently associated with significantly longer OS (Hazard Ratio [HR] = 0.62). This indicates that morning administration is associated with an approximate 38% reduction in the risk of death compared to afternoon administration.
05 Mechanistic Insights and Subgroup Observations
Regarding the underlying mechanism, Dr. Takemura K. cited studies in non-small cell lung cancer (NSCLC) suggesting that the immune system is typically more active in the morning; for instance, CD8-positive T cell counts are higher during morning hours, which may enhance the therapeutic response to ICIs. Notably, subgroup analysis revealed that the correlation between timing and efficacy was more pronounced in the ICI+TKI combination group than in the ICI+ICI group, a finding that warrants further biological investigation.
06 Conclusion and Outlook: A Cost-Neutral Clinical Optimization Strategy
Dr. Takemura K. concluded that this represents the largest cohort study to date in this field. Adjusting the timing of ICI administration serves as a “cost-neutral” strategy with high cost-effectiveness for mRCC management. However, as these findings are based on retrospective data, prospective validation is required. For current clinical practice, scheduling ICI infusions during morning slots when feasible may serve as a potential tactical optimization for patient outcomes.
